Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
BIO CEO & Investor Conference Format: "IPO Class of 2024 Panel" and one-on-one meetings Date: February 10, 2025 Location: New York, NY Registered conference attendees may schedule one-on-one meetings ...
Nature2mon
The renaissance of GSK3
Glycogen synthase kinase 3 (GSK3 ... Figure 5: Several signalling pathways induce the inhibition of GSK3 by phosphorylating the same serine residue near the amino terminus. Figure 6: The mechanism ...
Hosted on MSN29d
EMA gives OMPD to Actuate’s pancreatic cancer therapy
Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for elraglusib to treat pancreatic ductal adenocarcinoma (PDAC). The glycogen ...
Nature14d
Glutaminyl Cyclase Inhibitors and Alzheimer's Disease Research
In a notable study, researchers designed and synthesized novel compounds that act as dual inhibitors targeting both glutaminyl cyclase and glycogen synthase kinase-3β (GSK-3β), another enzyme ...